e1. Polman CH, O'Connor PW, Havrdova E. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. … England Journal of …. Epub 2006.

e2. Rudick RA, Stuart WH, Calabresi PA. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. … England Journal of …. Epub 2006.

e3. Kappos L, Radue E-W, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362:387–401.

e4. Cohen JA, Barkhof F, Comi G. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. … England Journal of …. Epub 2010.

e5. O'Connor P, Wolinsky JS, Confavreux C. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. … England Journal of …. Epub 2011.

e6. Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367:1098–1107.

e7. Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367:1087–1097.

e8. MD PJAC, PhD AJC, MD PDLA, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. The Lancet [online serial]. Elsevier Ltd; 2012;380:1819–1828. at: http://www.sciencedirect.com/science/article/pii/S0140673612617693.

e9. FRCP DAJC, MD CLT, MD PDLA, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. The Lancet. Elsevier Ltd; 2012;380:1829–1839.

e10. Cree BAC, Han J, Pradhan A, Masterman D, Williams MJ. Subgroup Analysis to Evaluate the Efficacy of Ocrelizumab Versus Interferon β-1a in African-Descended Patients With Relapsing Multiple Sclerosis in the OPERA I and OPERA II Studies (P639). European Committee for Treatment and Research in Multiple Sclerosis Berlin; 2018.

e11. Villar L, Garcia-Barragan N, Espiño M, et al. Influence of oligoclonal IgM specificity in multiple sclerosis disease course. Multiple Sclerosis. 2007;14:183–187.

e12. Kaufman M, Pardo G, Rossman H, Sweetser MT, Forrestal F, Duda P. Journal of the Neurological Sciences. J Neurol Sci. Elsevier B.V; 2014;341:22–27.

e13. McCarron MJ, Park PW, Fooksman DR. CD138 mediates selection of mature plasma cells by regulating their survival. Blood. 2017;129:2749–2759.

e14. Ligocki AJ, Rounds WH, Cameron EM, et al. Expansion of CD27high plasmablasts in transverse myelitis patients that utilize VH4 and JH6 genes and undergo extensive somatic hypermutation. Genes Immun. Nature Publishing Group; 2013;14:291–301.

e15. Byrd WC, Hughey MW. Biological Determinism and Racial Essentialism. Byrd WC, Hughey MW, editors. The ANNALS of the American Academy of Political and Social Science. 4 ed. 2015;661:8–22.